Abstract
The clinical benefits of immunotherapy are limited for unselected EGFR+ lung adenocarcinoma (LUAD). Conventional biomarkers like PD-L1 or TMB are not sufficient for these patients. Additionally, efficacy of EGFR-TKIs among EGFR+/TP53+ patients are significantly inferior to EGFR+/TP53- patients and subsequent treatment strategy are even more important. We conducted an integrated analysis to investigate the influence of TP53 mutation in immunotherapy efficacy and tumor microenvironment (TME) among EGFR+ LUAD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
